Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients

Medicine and Science in Sports and Exercise

Volumn 45, Issue 6, 2013, Pages 1043-1050

  Wooten, Joshua S ^a   Nambi, Preethi ^a   Gillard, Baiba K ^a   Pownall, Henry J ^a   Coraza, Ivonne ^a,b   Scott, Lynne W ^a,c   Nambi, Vijay ^a,c   Ballantyne, Christie M ^a,c   Balasubramanyam, Ashok ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b BEN TAUB GENERAL HOSPITAL   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

dyslipidemia; fenofibrate; niacin; Platelet activating factor acetylhydrolase; rantes

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; CCL5 PROTEIN, HUMAN; FENOFIBRATE; NICOTINIC ACID; RANTES;

ADULT; AGED; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; KINESIOTHERAPY; LIFESTYLE; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHEMOKINE CCL5; COMBINED MODALITY THERAPY; DIET THERAPY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE THERAPY; FEMALE; FENOFIBRATE; HIV INFECTIONS; HIV-1; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIFE STYLE; LINEAR MODELS; MALE; MIDDLE AGED; NIACIN; TREATMENT OUTCOME;

EID: 84878927019     PISSN: 01959131     EISSN: 15300315     Source Type: Journal    
DOI: 10.1249/MSS.0b013e3182843961     Document Type: Article

References (41)

1. Anogeianaki A, Angelucci D, Cianchetti E, et al. Atherosclerosis: a classic inflammatory disease. Int J Immunopathol Pharmacol. 2011; 24(4):817-25.
2. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis. 2003;168(1):107-13.
3. Balasubramanyam A, Coraza I, Smith EO, et al. Combination of ni-acin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of ''heart positive, '' a randomized, controlled trial. J Clin Endocrinol Metab. 2011;96(7):2236-47.
4. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104(25):3046-51.
5. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis. 2000;30(2 Suppl):S135-42.
6. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med. 2005;2(10):529-35.
7. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256(20): 2835-8.
8. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD. Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol. 2007;27(4):929-35.
9. Dube MP, Stein JH, Aberg JA, et al, Adult ACTGCS, and America HIVMAotIDSo. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003; 37(5):613-27.
10. Galli M, Ridolfo AL, Gervasoni C. Cardiovascular disease risk factors in HIV-infected patients in the HAART era. Ann N Y Acad Sci. 2001; 946:200-13.
11. Garcia JJ, Bote E, Hinchado MD, Ortega E. A single session of intense exercise improves the inflammatory response in healthy sedentary women. J Physiol Biochem. 2011;67(1):87-94.
12. Gaubatz JW, Gillard BK, Massey JB, et al. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). J Lipid Res. 2007; 48(2):348-57.
13. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab. 2001;12(9):413-9.
14. Group HPSC. Lipoprotein-associated phospholipase A(2) activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med. 2010;268(4):348-58.
15. Herder C, Peeters W, Illig T, et al. RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One. 2011;6(12):e25734.
16. Hulgan T, Sterling TR, Daugherty J, Arbogast PG, Raffanti S, Ray W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr. 2005;38(3):277-82.
17. Hurt-Camejo E, Camejo G, Peilot H, Oorni K, Kovanen P. Phos-pholipase A(2) in vascular disease. Circ Res. 2001;89(4):298-304.
18. James RW. Diabetes and other coronary heart disease risk equivalents. Curr Opin Lipidol. 2001;12(4):425-31.
19. Jones KL, Maguire JJ, Davenport AP. Chemokine receptor CCR5: from AIDS to atherosclerosis. Br J Pharmacol. 2011;162(7):1453-69.
20. Jones SP, Doran DA, Leatt PB, Maher B, Pirmohamed M. Short-term exercise training improves body composition and hyperlipid-aemia in HIV-positive individuals with lipodystrophy. AIDS. 2001; 15(15):2049-51.
21. Khovidhunkit W, Memon RA, Shigenaga JK, et al. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism. 1999;48(12):1524-31.
22. Kuvin JT, Dave DM, Sliney KA, et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006; 98(6):743-5.
23. Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol. 2006;9(3):138-43.
24. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012; 59(11):979-88.
25. Lozano JM, Kindelan JM, Cabello A, Gonzalez R, Solana R, Pena J. IL-2 increased RANTES production and CD25 expression in cultured PBMCs only from antiretroviral treated HIV-1+ patients with detectable viral loads. Int Immunopharmacol. 2006;6(6):1034-8.
26. Macphee CH, Nelson JJ, Zalewski A. Lipoprotein-associated phos-pholipase A2 as a target of therapy. Curr Opin Lipidol. 2005;16 (4):442-6.
27. Mooser V, Carr A. Antiretroviral therapy-associated hyperlipid-aemia in HIV disease. Curr Opin Lipidol. 2001;12(3):313-9.
28. Nomura S, Uehata S, Saito S, Osumi K, Ozeki Y, Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost. 2003;89(3):506-12.
29. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis. 2000; 31(3):787-97.
30. Perry SW, Hamilton JA, Tjoelker LW, et al. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem. 1998;273(28):17660-4.
31. Polo S, Veglia F, Malnati MS, et al. Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection. AIDS. 1999;13 (4):447-54.
32. Rosenson RS. Fenofibrate reduces lipoprotein associated phos-pholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J. 2008;155(3): 499.e9-16.
33. Sekhar RV, Jahoor F, Pownall HJ, et al. Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacy-lglycerolemia in HIV lipodystrophy syndrome. Am J Clin Nutr. 2005; 81(6):1405-10.
34. Tellis CC, Tselepis AD. The role of lipoprotein-associated phos-pholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791(5):327-38.
35. Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Med Sci Sports Exerc. 2006;38(3):411-7.
36. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phos-pholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010;375 (9725):1536-44.
37. Tsoupras AB, Chini M, Tsogas N, et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses. 2008;24(8):1079-86.
38. Virani SS, Nambi V, Hoogeveen R, et al. Relationship between circulating levels of RANTES (regulated on activation, normal T-cell expressed, and secreted) and carotid plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) Carotid MRI Study. Eur Heart J. 2011;32(4):459-68.
39. Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20(5):415-20.
40. Wong CK, White HD. Effects of dietary factors on lipoprotein-associated phospholipase A(2) (Lp-PLA (2)). Curr Atheroscler Rep. 2011;13(6):461-6.
41. Ye P, Kazanjian P, Kunkel SL, Kirschner DE. Lack of good correlation of serum CC-chemokine levels with human immunodeficiency virus-1 disease stage and response to treatment. J Lab Clin Med. 2004; 143(5):310-9.